A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission

Ulrika Morris1*, Mwinyi I. Mselle2, Humphrey Mkali2, Atiqul Islam1, Berit Aydin-Schmidt1, Irina Jovel1, Shija Joseph Shija2, Mwinyi Khamis2, Safia Mohammed Ali2, Lamija Hodzic1, Ellinor Magnusson1, Eugenie Poirot3, Adam Bennett3, Michael C. Sachs4, Joel Tarning5,6, Andreas Mårtensson7, Abdullah S. Ali2 and Anders Björkman1

Abstract

Background: Mass drug administration (MDA) has the potential to interrupt malaria transmission and has been suggested as a tool for malaria elimination in low-endemic settings. This study aimed to determine the effectiveness and safety of two rounds of MDA in Zanzibar, a pre-elimination setting.

Methods: A cluster randomised controlled trial was conducted in 16 areas considered as malaria hotspots, with an annual parasite index of > 0.8%. The areas were randomised to eight intervention and eight control clusters. The intervention included two rounds of MDA with dihydroartemisinin-piperaquine and single low-dose primaquine 4 weeks apart in May–June 2016. Primary and secondary outcomes were cumulative confirmed malaria case incidences 6 months post-MDA and parasite prevalences determined by PCR 3 months post-MDA. Additional outcomes included intervention coverage, treatment adherence, occurrence of adverse events, and cumulative incidences 3, 12, and 16 months post-MDA.

Results: Intervention coverage was 91.0% (9959/10944) and 87.7% (9355/10666) in the first and second rounds, respectively; self-reported adherence was 82.0% (881/1136) and 93.7% (985/1196). Adverse events were reported in 11.6% (147/1268) and 3.2% (37/1143) of post-MDA survey respondents after both rounds respectively. No serious adverse event was reported. No difference in cumulative malaria case incidence was observed between the control and intervention arms 6 months post-MDA (4.2 and 3.9 per 1000 population; p = 0.94). Neither was there a difference in PCR-determined parasite prevalences 3 months post-MDA (1.4% and 1.7%; OR = 1.0, p = 0.94), although having received at least the first MDA was associated with reduced odds of malaria infection (aOR = 0.35; p = 0.02). Among confirmed malaria cases at health facilities, 26.0% and 26.3% reported recent travel outside Zanzibar in the intervention and control shehias (aOR ≥ 85; p ≤ 0.001).

(Continued on next page)
**Background**

Global advances in malaria control have led to increased international commitment to malaria elimination [1]. A major challenge in achieving elimination is the identification and targeting of sub-microscopic and asymptomatic malaria infections, which are important for continued malaria transmission in low transmission settings [2, 3]. Mass testing and treatment (MTAT) and mass drug administration (MDA) are two potential strategies for targeting such infections [4]. MTAT involves screening all individuals in a given geographical area and treating those found positive for malaria. MTAT has been evaluated for use in malaria elimination settings, including Zanzibar [4, 5], but has not proven to influence transmission possibly due to low sensitivity of available diagnostic tools such as microscopy and rapid diagnostic tests (RDTs) [4, 6]. MDA is defined as the empiric administration of a therapeutic course of an antimalarial regimen to a defined population at the same time without screening or diagnostic testing prior to administration [7]. MDA has been a historic component of many malaria control and elimination programmes, but was until recently not recommended by the World Health Organization (WHO) due to concerns about efficacy, logistical feasibility, sustainability, and the risk of accelerating drug resistance [4]. However, limitations of currently available diagnostic tools and the development of efficacious antimalarials with transmission-reducing effects, such as artemisinin-based combination therapies and primaquine, have renewed the interest for MDA [7–9]. The WHO now supports MDA as an additional tool in low-endemic regions approaching interruption of transmission [4, 10].

Recent reviews have summarised the findings of MDA studies conducted in different settings in Asia, Africa, and the Americas [7, 8]. These studies employed a wide variety of MDA regimens incorporating different drugs, dosages, timings, and numbers of MDA rounds. In the first review in 2013, only two out of 32 included studies were conducted in areas of low endemicity (≤ 5% prevalence) [7, 11], and only two were designed as cluster randomised controlled trials (CRCTs) [11, 12]. Overall, the quality of evidence from areas of low endemicity was deemed to be very low [7]. In the more recent review, 48 out of 182 included studies had follow-up periods greater than 6 months. Only 12 of these 48 studies, conducted between 1961 and 2004, interrupted transmission for over 6 months post-MDA [8]. Only one of these 12 was conducted in sub-Saharan Africa. The consensus from both reviews is that MDA seems to have an immediate impact on malaria transmission, but only few studies have shown sustained impact beyond 6 months.

More recently, three pilot studies in Southeast Asia have shown over 90% reductions of the *Plasmodium falciparum* reservoir up to 12 months post-MDA [13–15]. In highly endemic villages in Eastern Myanmar, an uncontrolled before-and-after study of monthly MDA with dihydroartemisinin-piperaquine (DP) and single low dose (SLD) of primaquine showed a sustained fivefold decrease in *P. falciparum* incidence [16]. A recent CRCT conducted in low transmission areas (< 10% prevalence) in southern Zambia reported a short-term impact 5 months after two rounds of community-wide MDA with DP (odds ratio (OR) 0.13; p = 0.04) [17]. Finally, modelling has predicted that high coverage of repeated mass treatment may result in sustained transmission reduction when combined with vector control in low-endemic areas [18–20]. In conclusion, additional empirical evidence through high-quality CRCTs is clearly needed to determine the immediate and long-term impact of MDA, especially in low-endemic settings in sub-Saharan Africa where the goal is malaria elimination.

Zanzibar has, through high vector control coverage and good access to treatment, reached a state of malaria pre-elimination with low and seasonal transmission [21]. However, a persistent reservoir of sub-microscopic and asymptomatic infections remains an important obstacle in achieving elimination [22]. Zanzibar therefore represents an ideal situation to test MDA in the WHO recommended context of malaria elimination. A pilot MDA was conducted in response to a malaria outbreak in

**Trial registration:** ClinicalTrials.gov, NCT02721186 (registration date: March 29, 2016)

**Keywords:** Mass drug administration, Malaria, Elimination, Low transmission, Dihydroartemisinin-piperaquine, Single low-dose primaquine, Coverage, Adherence, Effectiveness, Safety
Zanzibar in 2013 [23]. Approximately 8800 inhabitants received a single round of MDA with DP. The MDA was well received by the community, with over 90% coverage and self-reported adherence. The impact of the intervention was, however, not monitored. In our present study, a CRCT was conducted to primarily assess the effectiveness and safety of two rounds of MDA with DP given together with SLD primaquine, for reducing seasonal malaria transmission towards its elimination in Zanzibar. Two rounds of MDA were chosen to maintain a balance between cost, feasibility, and impact. Importantly, this study adds to the limited evidence for the use of MDA in low transmission settings in sub-Saharan Africa, a primary goal for MDA [4].

Methods
Study design
Study setting and population
A two-armed, open-label CRCT was conducted in 16 shehias (smallest administrative units with typically 2000–5000 inhabitants) in central, south, and west districts on Unguja Island, Zanzibar (Fig. 1). The intervention and control arm each contained eight clusters defined as hotspot shehias with an annual parasite index (API) in 2015 of > 8/1000 population. The API was estimated as the number of confirmed malaria infections reported at health facilities and/or detected during active case detection over the estimated shehia population. The shehia population was based on a consensus survey conducted in 2012 and a population growth of 2.8%. Eligible hotspot shehias were those in the three study districts with a population under 2500.

The entire study population received the standard of care offered by the Zanzibar Ministry of Health and Social Welfare, consisting of diagnosis by RDT or microscopy of clinically suspected malaria in persons presenting to health care centres. Individuals with parasitological diagnosis of malaria at health facilities (hereinafter referred to as “malaria cases”) were treated with first-line drug artesunate-amodiaquine alone. Health care was primarily provided through 15 public health facilities in the 16 shehias.

Universal distribution of long-lasting insecticide-treated nets (LLINs) was conducted in 2012–2013 and 2015–2016 across Zanzibar. The latter distribution was divided in two phases. Approximately one third of the shehias in Unguja received nets in April 2015, including all but two of the study shehias (both in the intervention arm). The remaining shehias received nets in June–July 2016. In addition to these mass campaigns, continuous net distribution has been conducted in all shehias since 2013 targeting pregnant women, children under five, and households with no or worn-out nets.

Zanzibar switched from universal indoor residual spraying (IRS) with pyrethroids to focal targeting of hotspots with carbamate insecticides in 2012. Annual rounds of targeted IRS have since 2014 been conducted with pirimiphos methyl (Actellic® 300CS, Syngenta), a long-lasting insecticide formulation designed for control of pyrethroid-resistant mosquitoes. All study shehias in 2016 and all but 2 shehias (one in each study arm) in 2015 were targeted by IRS.

Study intervention
Two rounds of MDA with DP (D-ARTEPP, Guilin Pharmaceutical (Shanghai) Co., Ltd., China) and SLD (0.25 mg/kg) primaquine (Remedica Ltd., Cyprus) were
conducted 4 weeks apart in the intervention arm in May–June 2016. Infants under 6 months, women who were either pregnant in the first trimester or whose pregnancy status was unknown (see treatment guidelines, Additional file 1), individuals presenting with severe illness that impaired performance of daily activities, and those having taken antimalarial treatment during the last 14 days were excluded from treatment. In addition, all pregnant women and women breastfeeding infants under 6 months were excluded from treatment with SLD primaquine.

**Outcome measures**

The primary outcome was the cumulative confirmed malaria case incidences in the intervention and control shehias 6 months after the second round of MDA. Confirmed malaria cases were reported in real time through the malaria case notification system (MCN) at health facilities, together with additional information regarding shehia of residence, vector control coverage and uptake, age, sex, and travel history in the last 30 days. Confirmed malaria case incidence was defined as the number of malaria cases in study shehia residents, standardised against the population size estimated at the baseline of the survey to obtain the incidence per 1000 population. The secondary outcome was the community prevalence of malaria infections determined by polymerase chain reaction (PCR) 3 months post-MDA. Additional outcomes included intervention coverage, adherence to the 3-day treatment regimen, occurrence of adverse events, and cumulative incidences 3, 12, and 16 months post-MDA.

**Study procedures**

**Community sensitisation**

Community sensitization was conducted prior to study onset to maximise study participation. Village leaders and community members were invited to attend informational meetings held in all 16 shehias; additional meetings were held in the eight intervention shehias before the second round of treatment. Information leaflets were distributed to all households with key messages regarding the study objectives and procedures. Specific information regarding the study drugs and management of possible adverse effects was targeted to the intervention arm only. Local village assistants made public announcements the day before the survey. Automated text messages were sent on two consecutive days after MDA to households where a mobile phone number had been provided to remind participants to take DP doses 2 and 3 and where to go in the case of adverse events.

**Population enumeration**

Population enumeration was conducted in all 16 shehias in association with the first round of MDA (April 30–May 17, 2016). A de facto population approach was used in which all persons sleeping in the household the night before the survey were enumerated (i.e. both permanent and temporary residents). Neighbours were asked to report the number of residents in empty households. Data regarding demographics, uptake of malaria control interventions, known malaria risk factors such as travel history, and eligibility for treatment were collected digitally using Open Data Kit software on tablet computers.

**Treatment administration and coverage**

Teams of two trained health care workers accompanied by a local guide, distributed treatment to eligible individuals in the intervention shehias during house-to-house visits. Tablet computers were programmed to provide age-based treatment guidelines (see treatment guidelines, Additional file 1) for eligible individuals. Children were given a packet of biscuits for eating after drug intake to prevent abdominal pain, nausea, and vomiting. Persons present during household visits were provided the first drug dose (DP + SLD primaquine) under supervision. The additional two DP doses were left in individual packets with clear instructions for unsupervised intake at home. Labelled packets containing all three doses were left with the head of household for individuals not present. Distribution activities commenced around 8 am and were often completed by 2–4 pm. Children < 8 years who were not present (mainly due to school or after school religious studies) were excluded from receiving the volume-based paediatric dosing of SLD primaquine (Fig. 2). Schoolchildren were therefore asked, with permission from schoolteachers and village leaders, to stay at home on the day of MDA. Efforts were made to revisit households with missing household members later the same day. Coverage was determined as the proportions of the population registered in each round of MDA that received treatment. The proportions of the total population, i.e. the estimated number of people registered in either treatment round (see demographic data collection, Additional file 1), having received zero, one, or two rounds of MDA, were also assessed.

**Post-MDA surveys and adherence to the 3-day treatment regimen**

Post-MDA surveys were conducted in a subset of the population (34 households/shehia) in the intervention arm 7 days after each treatment round. All household members were asked regarding their perception of MDA. Individuals who reported receiving treatment were asked questions regarding adherence and occurrence of adverse events. The self-reported adherence was determined as the proportion of respondents reporting having completed all three doses of DP.

To validate self-reported adherence, finger-prick blood samples to measure day 7 piperaquine blood
concentrations were collected from adult participants aged 14 years and older (N = 239) during the first post-MDA survey. Blood samples were also collected from adults (N = 108) selected from 10 households in each shehia who had taken all three doses of DP under direct observation (observed intake control group). A capillary tube was used to transfer 100 μL blood from the finger to pre-labelled Whatman 31 ETCHR filter papers. Piperaquine whole blood concentrations were measured using solid-phase extraction and liquid chromatography mass-spectrometry at the Department of Clinical Pharmacology, Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand. Quality control standards at 9.00 ng/ml, 40.0 ng/ml, and 800 ng/ml were analysed with each batch of clinical samples to ensure high in-assay precision (i.e. relative standard deviation of < 5%). The reportable range of drug concentrations was 2.4–1150 ng/ml.

**Active and passive monitoring of adverse events**

The occurrence of adverse events was actively monitored using a structured questionnaire during post-MDA surveys. Respondents were asked to report side effects from a list of possible events, together with perceived severity (mild, moderate, or severe) and date of onset and duration. Adverse events were also passively monitored at health facilities by trained health workers for a period of 14 days after each MDA round. Participants were instructed to present to the local health facilities should they experience adverse events such as vomiting, nausea, gastrointestinal upset, rash, fatigue, or dark urine. A standardised form adapted to the study context was used to capture possible serious adverse events following SLD primaquine treatment [24]. In addition, haemoglobin levels and urine colour were measured for assessing the presence of haemoglobinuria or haemolysis (haemoglobin < 5 g/dl or Hillmen colour chart score ≥ 5).

**Follow-up survey and community prevalence of malaria infection**

A follow-up survey, consisting of a tablet-based questionnaire covering uptake of control interventions, risk factors associated with malaria, and perception of MDA, was conducted 3 months post-MDA (Aug 30–Sept 9) in approximately 50% of households in the study area. Finger-prick blood sampling on a Whatman 3MM filter paper for estimating PCR-determined parasite prevalence was conducted in all ages during follow-up (N = 9849), as well as at the study baseline (N = 7941). Approximately 100 μL of blood was collected on pre-labelled filter papers; molecular analyses were conducted at Karolinska Institutet, Stockholm, Sweden. In brief, DNA was extracted from pools of four samples using the Chelex-100 boiling method with minor modifications (see laboratory protocols, Additional file 1). Extracted pools were screened for *Plasmodium* DNA with two different quantitative PCRs (qPCR): cytochrome b (Cytb) qPCR [25] and 18s-qPCR [26]). Individual samples in pools considered positive by either PCR method were re-extracted and subjected to screening with Cytb-qPCR in baseline samples, or both Cytb-qPCR and 18s-qPCR in follow-up samples. *Plasmodium* species was determined by restriction fragment length polymorphism [25]; 18s-qPCR was repeated in triplicate to estimate parasite densities [22, 26].

**Sample size calculation and randomisation**

Sample size calculation for the CRCT was based on the incidence of reported malaria cases during the period May–October 2015. After restricting to the 26 highest incidence shehias with a population under 2500 in the three study districts, the calculated coefficient of variation was 0.35. Using this coefficient of variation, a (harmonic) mean shehia population of 1405, and a baseline incidence of 12/1000, eight clusters in each arm.
Statistical analyses
Analyses were intention-to-treat analyses wherein all individuals in the intervention arm were assumed to have received treatment. Unadjusted comparisons of the cumulative malaria case incidence in the intervention and control shehias were conducted at 3, 6 (primary outcome), 12, and 16 months post-MDA. Analyses were done using Wilcoxon rank-sum test with exact statistics, on cluster summaries of cumulative incidence. Cumulative malaria case incidences before and after MDA were compared by Wilcoxon signed-rank test with exact statistics. Parasite prevalence by PCR was compared between study arms by estimating ORs in logistic regression models using generalised estimating equations (GEE) accounting for clustering by shehia. Additional exploratory analyses included univariate and multivariate analyses of risk factors associated with clinical malaria and asymptomatic infections. Individual malaria case data collected in MCN, on risk factors associated with clinical malaria, were compared with corresponding data collected from the general population in the baseline survey. Risk factors associated with asymptomatic malaria were compared at baseline and follow-up in PCR-positive and PCR-negative persons. Risk factor analyses were conducted by logistic regression using GEE with OR as a measure of association; all variables were included in the model for adjusted odds ratios (aOR). Median day 7 piperaquine concentrations were compared between groups by the Wilcoxon rank-sum test. All analyses were conducted using Stata v.12.0, apart from crude incidence rate ratio that was calculated in OpenEpi [27].

Results
Baseline characteristics
In total, 23,251 people living in 5688 households were registered at the study baseline. Household participation rate was high; < 0.5% of household heads refused participation, and 5.4% of households were empty or not occupied at the time of the survey. Baseline characteristics were similar between the two arms (Table 1). There was no significant difference in the pre-intervention annual parasite incidence ($p = 0.19$), but the PCR-determined malaria prevalence was significantly lower in the intervention arm than in the control arm at baseline ($OR = 0.31$, CI95% 0.15–0.61, $p = 0.001$).

Coverage of MDA
Coverage with DP treatment was 91.0% (range between shehias 87.1–93.4%) and 87.7% (78.3–92.8%) in the first and second rounds, respectively. Coverage with SLD primaquine was 86.2% (82.1–89.2%) and 80.5% (69.8–87.2%) (Fig. 2). Of the total population registered in the intervention shehias ($N = 12,614$), 60.6% (range between shehias 49.5–72.9%) received both rounds of MDA, 18.4% (14.1–24.2%) received round 1 only, 13.6% (7.2–19.5%) received round 2 only, and 7.4% (4.6–10.4%) did not receive any MDA. Hence, 92.6% (89.6–95.4%) of the population were reached with at least one treatment round.

Women with uncertain pregnancy status (10.9% and 7.1% of adult women in each round) were the largest group excluded from treatment with DP (Fig. 2). Children under 8 years of age who were not present (9.1% and 19.4% of children < 8 years in each round) were the largest group excluded from treatment with SLD primaquine. Among eligible individuals in each round, only 0.5% and 1.8% refused treatment. The most common reason for refusing treatment was fear of side effects (reported by 50.4% of refusals). In the second round, more participants requested to take the medicine in the evening to avoid experiencing side effects. This resulted in fewer participants (48.0% vs. 67.4% in the first round) having taken the first dose under observation.

Adherence to the 3-day treatment regimen and adequate drug exposure
Self-reported adherence to the 3-day treatment regimen was 82.0% (range between shehias 71.9–88.6%) and 93.7% (83.7–99.3%) for rounds 1 and 2, respectively (Fig. 3). The main reason for not completing the treatment was experiencing side effects (50.1% of non-completed treatments). The self-reported adherence corresponded with day 7 piperaquine concentrations at the group level (Table 2). There was no significant difference in the median concentrations between the observed intake control group and those reporting full adherence ($p = 0.19$), whilst median drug concentrations were significantly lower in those reporting non-adherence ($p < 0.001$). However, among adults who claimed full adherence, 7.4% (16/215) showed piperaquine concentrations below the limit of quantification indicating incomplete treatment intake (see Additional file 2: Figure S1). Taking into account this overestimation of adherence, an estimated 69.1% and 76.1% (mean 72.6%) of the registered population were covered by adequate drug exposure (i.e. having received and completed the full treatment course) in rounds 1 and 2, respectively.
Safety and tolerability of MDA

Among post-MDA survey respondents who received treatment, 147/1268 (11.6%; range between shehias 5.7–23.8%) and 37/1143 (3.2%; 0.6–8.8%) reported at least one adverse event after the first and second rounds, respectively. In addition, there were 85 and 29
reports of adverse events passively identified at health facilities after rounds 1 and 2. Nausea and vomiting (33.1% of all reports), stomach pain and diarrhoea (18.9%), and dizziness, headache, and fatigue (23.5%) were the most commonly reported adverse events (see Additional file 3: Table S1). Across all adverse events, 44.1% were perceived by survey respondents as mild, 52.0% as moderate, and 0.5% as severe. No MDA-associated deaths or other clinically serious adverse event was reported.

In post-MDA and the follow-up surveys, 1761/1786 (98.6%) and 8115/8966 (90.5%) of present respondents expressed willingness to participate in future MDAs. Even among those who reported adverse events, 146/151 (96.7%) would participate in MDA again.

### Impact of MDA on malaria transmission

**Confirmed malaria case incidence**

No difference in cumulative malaria case incidence was observed between the control and intervention arms 6 months after MDA (4.2 and 3.9 per 1000 population, respectively; corresponding to a crude incidence rate ratio of 0.94 CI95% 0.63–1.44). Neither was there a difference in cumulative malaria incidence at 3, 12, and 16 months after MDA, or when only locally acquired infections were considered, i.e. excluding those reporting overnight travel to mainland Tanzania in the last month (Table 3). However, there was a 62.6% reduction in cumulative malaria incidence from 10.9 to 4.1 per 1000 population ($p < 0.001$) across both study arms in 2016 (Fig. 4). This reduction was observed across all of

### Table 2 Day 7 piperaquine concentrations by adherence status

| Adherence Status | Median drug concentration ng/ml [IQR] | p value\(^1\) |
|------------------|--------------------------------------|--------------|
| Observed intake control group (N = 94)\(^2\) | 128.5 [53.5–189.0] | Reference |
| Non-observed treatment intake (N = 236)\(^3\) | 95.5 [34.9–186.0] | 0.051 |
| Self-reported adherence | | |
| Full adherence (N = 215) | 107.0 [41.0–192.0] | 0.187 |
| Non-adherence (N = 21) | 30.4 [2.9–69.6] | < 0.001 |
| Self-reported non-adherence | | |
| Completed two doses (N = 8) | 57.8 [3.3–100.7] | 0.034 |
| Completed one dose (N = 11) | 36.8 [2.9–60.9] | 0.001 |
| Completed no doses (N = 2) | 7.1 [<LLOQ–12.9] | 0.017 |

\(^1\)Calculated by the two-sample Wilcoxon rank-sum (Mann-Whitney) test against the observed intake control group. Significant p values are set in italics

\(^2\)Ten samples with drug concentration falling below the limit of quantification (<LLOQ), three samples with reports of vomiting within 30 min after drug intake, and one sample with self-reported non-adherence were excluded from the control group

\(^3\)Three samples excluded due to improper sample conditions
### Table 3 Cumulative malaria case incidence at 3, 6, 12, and 16 months after MDA

| Time period                  | Malaria cases | Cumulative incidence (cases/1000 population; range between shehias) | p value |
|------------------------------|---------------|---------------------------------------------------------------------|---------|
|                              | Intervention  | Control                                                             |         |
|                              | (N = 10,944)  | (N = 12,307)                                                        |         |
| Baseline                     |               |                                                                     |         |
| 6 months (May–Nov 2015)      | 128           | 126                                                                  | 11.7; 7.7–16.1 | 10.2; 6.4–32.8 | 0.130 |
| 12 months (May 2015–April 2016) | 150           | 146                                                                 | 13.7; 9.8–19.6 | 11.9; 7.5–36.8 | 0.105 |
| Post-MDA                     |               |                                                                     |         |
| 3 months (May–Aug 2016)      | 31            | 41                                                                  | 2.8; 0.0–10.3 | 3.3; 0.9–8.0 | 0.721 |
| 6 months (May–Nov 2016)      | 43            | 52                                                                  | 3.9; 0.0–13.1 | 4.2; 2.1–8.0 | 0.442 |
| 12 months (May 2016–April 2017) | 58            | 71                                                                  | 5.3; 0.0–13.1 | 5.8; 3.1–10.4 | 0.382 |
| 16 months (May 2016–Aug 2017) | 143           | 208                                                                 | 13.1; 5.4–28.0 | 16.9; 6.7–31.8 | 0.130 |
| Post-MDA cases without travel history |       |                                                                     |         |
| 3 months (May–Aug 2016)      | 18            | 23                                                                  | 1.6; 0.0–9.3 | 1.9; 0.0–8.0 | 0.716 |
| 6 months (May–Nov 2016)      | 22            | 29                                                                  | 2.0; 0.0–11.2 | 2.4; 0.9–8.0 | 0.277 |
| 12 months (May 2016–April 2017) | 31            | 41                                                                  | 2.8; 0.0–11.2 | 3.3; 1.1–8.0 | 0.315 |
| 16 months (May 2016–Aug 2017) | 109           | 160                                                                 | 10.0; 5.4–26.1 | 13.0; 2.7–30.8 | 0.279 |

*Primary outcome*

---

**Fig. 4** Confirmed malaria case incidence rates as reported in MCN before and after MDA. Error bars represent the range in monthly incidence rates in the control (red) and intervention (green) shehias. Horizontal bars represent the monthly rainfall on Unguja according to the Tanzanian Meteorological Agency Zanzibar Office. The blue bars under the x-axes represent the timing of IRS with Actellic®300CS, which is conducted annually in Feb–March in hotspot shehias. The yellow bars represent the two phases of the universal LLIN distribution in April 2015 and June–July 2016. The green bars indicate the timing of the two rounds of MDA (30 April–7 May and 28 May–4 June, respectively). The orange bar indicates the timing of the follow-up survey (30 Aug–9 Sept), and the primary endpoint of the study (30 Nov) is marked out with a black arrowhead.
Unguja Island in 2016 (see Additional file 2: Figure S2). There was no apparent difference in annual rainfall profiles 2015–2017, although the seasonal rains in April–June 2016 were of shorter duration.

**PCR-determined prevalence of Plasmodium infection**

No difference in PCR-determined parasite prevalence was observed between the intervention and control shehias in the follow-up survey (OR = 1.0, CI95% 0.5–2.0, p = 0.94) (Table 4). Similar findings were observed after excluding individuals with reported overnight travel (OR = 1.0, CI95% 0.5–2.1, p = 0.94). *P. falciparum* was the predominant species, followed by *P. malariae* and *P. ovale*, with mean parasite densities around 10 parasites/μL (Table 4). Some 3303 individuals were screened by PCR in both baseline and follow-up surveys. Four individuals were positive for malaria by PCR in both surveys; all four were residents of control shehias. Among the 82 PCR-positive individuals in the follow-up survey in the intervention shehias, 45 (54.9%) had received both treatment rounds, 17 (20.7%) had received either round 1 or 2, and 20 (24.4%) had received no treatment.

**Risk factors associated with clinical and asymptomatic malaria infection**

Among clinical cases, being 15–24 years old, male, and having travelled outside of Zanzibar were all strongly associated with increased odds of infection in both the intervention and control shehias (Table 5). Among confirmed malaria cases in the intervention and control shehias, 26.0% and 26.3% reported recent travel outside Zanzibar, respectively (aOR = 0.52; CI95% 0.29–0.93, p = 0.03) were the only factors significantly associated with reduced odds of infection. The association with only having received the second round of treatment was not significant (aOR = 0.80; CI95% 0.37–1.73, p = 0.57). In the control shehias, being 15–24 years old and residing in a household covered by vector control (either IRS or LLIN) were associated with increased and decreased odds of infection 3 months post-MDA, respectively.

**Discussion**

Two rounds of MDA were implemented in a population of over 10,000 people in areas considered hotspots in Zanzibar. High intervention coverage and adherence (> 80%) was achieved in each treatment round, and MDA was well tolerated and accepted by the community. Despite successful implementation, residing in a household covered by IRS and use of a mosquito net the night before the survey were associated with lower odds of infection in the intervention shehias but not in the control shehias.

Similar associations were observed among asymptomatic infections. At study baseline (see Additional file 3: Table S2a), being 15–24 years old, male, and having travelled outside of Zanzibar in the last 6 months was associated with an increased odds of PCR-detected infection. Residing in households covered by IRS was associated with lower odds of asymptomatic infection. These associations were, however, not as prominent in the follow-up survey (see Additional file 3: Table S2b). In the intervention arm, having received the first (aOR = 0.35; CI95% 0.14–0.86, p = 0.02) or both rounds of MDA (aOR = 0.52; CI95% 0.29–0.93, p = 0.03) were the only factors significantly associated with reduced odds of infection. The association with only having received the second round of treatment was not significant (aOR = 0.80; CI95% 0.37–1.73, p = 0.57). In the control shehias, being 15–24 years old and residing in a household covered by vector control (either IRS or LLIN) were associated with increased and decreased odds of infection 3 months post-MDA, respectively.

**Table 4** PCR-determined prevalence of *Plasmodium* infection at baseline and during follow-up surveys

|                      | Baseline | Follow-up |
|----------------------|----------|-----------|
|                      | Intervention | Control | Total | Intervention | Control | Total |
| **Prevalence n/N**   | 31/4042 (0.8; 0.0–1.6) | 95/3875 (2.5; 0.7–4.5) | 126/7917 (1.6; 0.0–4.5) | 82/4896 (1.7; 0.5–3.9) | 71/4905 (1.4; 0.5–4.0) | 153/9801 (1.6, 0.5–4.0) |
| (%; range between shehias) | 28/4042 (0.7; 0.0–1.6) | 90/3875 (2.3; 0.7–4.5) | 118/7917 (1.5; 0.0–5.0) | 79/4896 (1.6; 0.6–3.9) | 68/4905 (1.4; 0.5–4.1) | 147/9801 (1.5,0.5–4.0) |
| **Malaria species**   |          |          |       |
| *P. falciparum* (N, %) | 22; 71.0% | 64; 67.4% | 86; 68.3% | 61; 74.4% | 47; 66.2% | 108; 70.6% |
| *P. malariae* (N, %) | 2; 6.5% | 17; 17.9% | 19; 15.1% | 7; 8.5% | 11; 15.5% | 18; 11.8% |
| *P. ovale* (N, %)   | 4; 12.9% | 1; 1.1% | 5; 4.0% | 5; 6.1% | 7; 9.9% | 12; 7.8% |
| *P. vivax* (N, %) | 1; 3.2% | 0; 0.0% | 1; 0.8% | 1; 1.2% | 0; 0.0% | 1; 0.7 |
| Mixed infections (N, %) | 2; 6.5% | 12; 12.6% | 14; 11.1% | 6; 7.3% | 6; 8.5% | 12; 7.8% |
| Undetermined (N, %) | 0; 0.0% | 1; 1.1% | 1; 0.8% | 2; 2.4% | 0; 0.0% | 2; 1.3% |
| **Parasite densities** |          |          |       |
| Geometric mean p/μL (IQR) | 8 [2–21] | 8 [<1–50] | 8 [<1–43] | 11 [<1–57] | 3 [<1–21] | 6 [<1–35] |
| Samples <LLOQ (N, %) | 6; 19.4% | 29; 30.5% | 35; 27.8% | 43; 52.4% | 30; 42.2% | 73; 47.7% |

1Mixed infections were either *P. falciparum* + *P. malariae* (88.5% of mixed infection) or *P. falciparum* + *P. ovale* (11.5% of mixed infections)
2Parasite densities below the limit of quantification (1 p/μL) were set as 0.5 p/μL; IQR = interquartile range
3< LLOQ = below lower limit of quantification, i.e. samples that were positive in cytb-qPCR but negative in the 18s-qPCR for quantification
no difference in malaria transmission was observed between the intervention and control arms in this pre-elimination setting. Multiple rounds of MDA with high intervention coverage (i.e. over 80%) are deemed necessary when MDA is used to reduce transmission or eliminate malaria [8, 10]. Coverage is generally determined based on the amount of drugs dispensed and the number of persons targeted in each treatment round. This method may, however, overestimate treatment coverage if missing persons and mobile populations are not correctly accounted for [4].

In our study, population sizes were estimated from a census survey conducted in 2012 and IRS survey data from 2016. Similar numbers were obtained at the study baseline enumeration (data not shown), suggesting that the majority of the study population had been recorded.

The coverage in each treatment round was 91.0% and 87.7%. High coverage is, however, only effective if an adequate number of people correctly complete the full course of antimalarial treatment [10]. Adherence is especially an issue when treatment is provided to individuals who are not sick. Adherence measurements mostly rely on self-reporting, but this may be subject to recall bias or over reporting. We therefore validated the self-reported adherence using day 7 piperaquine blood concentrations. This enabled an overall mean estimate regarding effective coverage (i.e. the proportion of the population completing the full treatment course) of 72.6% in each round.

The high coverage and compliance achieved in this study may partly be due to the familiarity of MDA as an intervention through its previous use in control and intervention regions. This enabled an overall mean estimate of effective coverage of 72.6% in each round. The intervention through its previous use in control and intervention settings was partly due to the familiarity of MDA as an intervention through its previous use in control and intervention settings.

### Table 5

| Table 5 Univariate and multivariable analysis of risk factors associated with clinical malaria infections |
|-----------------------------------------------|
| **Intervention shehias** | **Survey population (n; %)** | Malaria cases (n; %)** | OR (CI95%) | aOR1 (CI95%) | p value |
| No | 1316; 12.5 | 18; 23.4 | 1 (Ref) | 1 (Ref) | – |
| Yes | 9218; 87.5 | 59; 6.6 | 0.4; 0.3–0.7 | 0.5; 0.2–0.9 | 0.018 |

| **Control shehias** | **Survey population (n; %)** | Malaria cases (n; %)** | OR (CI95%) | aOR3 (CI95%) | p value |
| No | 1283; 12.2 | 9; 11.7 | 1 (Ref) | 1 (Ref) | – |
| Yes | 9251; 87.8 | 68; 8.3 | 1.0; 0.5–2.0 | 2.8; 0.9–9.1 | 0.085 |

*Healthy individuals at study baseline: N_{intervention shehias} = 10,534; N_{control shehias} = 11,642; 194 (0.9%) individuals excluded due to missing data, and 126 (0.6%) excluded for being positive for malaria by PCR*  
*Malaria cases diagnosed at health facilities during the study period May 2016–August 2017: N_{intervention shehias} = 77; N_{control shehias} = 133; 141 (40.2%) individuals excluded due to missing data*  
*All variables were included in the model of adjusted OR; significant p values are presented in italics*
elimination of schistosomiasis and lymphatic filariasis [28, 29], as well as historic and more recent use in malaria control [23, 30]. Community engagement to build awareness of MDA for asymptomatic malaria and partnerships between researchers, local volunteers, and authorities are also factors noted to contribute to high intervention uptake [23, 30–34]. These factors were considered in the community sensitisation that was conducted prior to the study start. In addition, over half of the head of households still recognise malaria as a health concern (Table 1) despite substantial reductions in malaria morbidity and mortality in Zanzibar, potentially adding to the high uptake of the intervention. Another important component for achieving adequate adherence is the safety and tolerability of the treatment regimen [10]. Pharmacovigilance in this study was planned to ensure training, detection, reporting, management, and follow-up of adverse events by both passive and active surveillance. In line with other studies [13, 14, 16, 34–37], MDA with DP and SLD primaquine was deemed safe, with some transient adverse events and no reports of clinically serious adverse events. In addition, acceptability of the intervention was high with over 90% of survey respondents expressing willingness to participate in future MDAs.

Although high coverage and compliance were achieved, no significant impact on transmission was observed, although having received at least the first MDA was partly protective against asymptomatic infection 3 months post-MDA (aOR = 0.35; p = 0.02). Previous studies evaluating the impact of MDA have had varying results [7, 8, 13, 15–17, 30]. Overall, MDA has mostly shown short-term impact on malaria transmission, and only a few studies have provided sustained results [14–16, 38]. Recent studies have shown MDA to have an added effect in areas already experiencing a decline in the malaria burden, when deployed together with enhanced early diagnosis and treatment and supporting interventions that target malaria vectors [13–17]. The study in Zambia is the only previous CRCT showing impact of MDA in a low-endemic area in sub-Saharan Africa [17]. This study reported a reduction in malaria prevalence 5 months after two rounds of MDA with DP, albeit with weak statistical significance (aOR 0.13, CI95% 0.02–0.92, p = 0.04).

The optimal transmission scenarios and drug intervention regimens for producing a sustained impact with MDA thus remain largely unknown, and it remains unclear when MDA may be of most benefit in the context of malaria elimination [39]. DP has been suggested as a suitable option for MDA, in view of its good efficacy, long post-treatment prophylaxis, and good tolerability [10]. The addition of SLD primaquine is recommended to further reduce the transmissibility of *P. falciparum* gametocytes in areas of low transmission [10, 40]. The number of treatment rounds required to obtain a sustained effect of MDA is however unclear. A single year of two rounds of MDA with an effective coverage of 70% is estimated to provide 14–35% reduction in *P. falciparum* prevalence 2 years after MDA [18]. Modelling suggests that increased number of rounds improves the effectiveness, with a greater sustained impact of MDA if continued over 2 years rather than one. The aim of successive rounds is total coverage, i.e. reaching people who were initially missed and people who were treated in the previous rounds but may have been re-infected after MDA [10, 18]. Adding a third treatment round with 70% effective coverage in models only improved effectiveness if additional people were reached who had not previously received treatment [18]. We estimated a mean effective coverage of 72.6% in each treatment round, with 60.6% of the population having received both rounds and 92.6% of the population having received at least one round. Whether or not this coverage is sufficient remains unclear. Perhaps, higher effective coverage of at least two consecutive rounds of MDA is required to provide a long enough prophylactic period to protect against reinfection from infected mosquitoes (i.e. covering a full man-mosquito-man cycle) in a population.

High coverage of consecutive MDA rounds may be especially important in low-endemic areas where imported malaria cases (which may not be affected by MDA) are expected to have a greater relative contribution to transmission [18]. In Zanzibar, the proportion of clinical malaria cases reporting travel has increased in recent years, clearly indicating imported malaria to be an important driver of remaining transmission (Björkman et al. submitted). In the present study, over a quarter of clinical malaria cases reported overnight stay outside of Zanzibar in the last month (Table 5) compared to less than 1% in the general population (Table 1). We therefore, suggest that two rounds of MDA in a single year may not be sufficient to have a sustained impact on transmission in a pre-elimination setting, especially when the impact of MDA is restricted by imported malaria.

Another possible explanation for the lack of impact on transmission could be the timing of the MDA. Modelling has predicted less influence on malaria transmission if MDA is conducted during peak transmission [18, 19]. It is therefore recommended in areas of seasonal transmission that MDA be deployed immediately before the start of the main transmission season [4, 9, 10, 14, 18]. The onset of this study was delayed due to political elections, and due to difficulties in importation and registration of the study drugs. The first round of MDA was conducted right at the beginning of the high transmission season and the second round during peak transmission (see Additional file 2: Figure S3). Having received the first
round of treatment was indeed associated with reduced odds of PCR-detected malaria infection in the follow-up survey, whilst having only received the second round of treatment was not (see Additional file 3: Table S2b). These data suggest that there may have been a short and transient effect of MDA on local transmission, which had already been diluted when the follow-up survey was conducted 3 months post-MDA. In addition, the difference in the timing of the baseline surveys in the intervention and control shehias (see Additional file 2: Figure S3) may partly explain the difference in malaria prevalence at the study baseline (Table 1). This difference may however also be due to chance since the potential for imbalance across treatment groups despite randomisation is greater in a relatively small number of clusters.

Importantly, the ability to assess the true effectiveness of MDA in this study was affected by the overall decline in malaria transmission that occurred across Unguja island in 2016 (Fig. 4 and Additional file 2: Figure S2). The study was powered to detect a 50% drop in cumulative malaria incidence from 12/1000 to 6/1000 population in the intervention arm during the 6 months following MDA. However, the observed cumulative incidence (4.2/1000) in the control arm was lower than predicted (Table 3). Assessing the impact of interventions in low transmission settings is problematic, not only because it is difficult to achieve great enough power, but also because transmission may be geographically and temporally heterogeneous from year to year. Several other studies have also reported a decline in transmission across study arms [11, 13, 15, 17]. These studies, including the CRCT conducted in Zambia, have largely attributed these declines to the continuing effects of additional interventions such as high coverage with vector control and strong case management and surveillance. It has been argued that these additional interventions are a prerequisite for implementing MDA [17], but when all interventions are introduced simultaneously, the resulting large reductions in incidence may potentially mask the additional impact of MDA. In Zanzibar on the other hand, high vector control coverage, strong malaria case management, and malaria surveillance have been in place since 2008. Actellic®300CS has been in use since 2014 in the annual targetting of malaria hotspots with IRS, and continued high uptake of bed net usage has been reported in this study as well as elsewhere (Björkman et al., submitted). These additional interventions can therefore not explain the large decline in transmission observed across Zanzibar in 2016. Another more likely explanation for the reduction in transmission is the year-to-year fluctuations in climate [41]. Despite there not being any obvious difference in the total rainfall, the rains in 2016 were short and intense and stopped early with a very dry May compared to 2015 and 2017 (Additional file 2: Figure S2).

Overall, these general declines in transmission across study arms highlight the importance of a cluster randomised study design when evaluating the impact of MDA on malaria transmission [17, 30, 39].

**Conclusions**

MDA was implemented with high coverage, adherence, and tolerability in Zanzibar. Despite this, no significant impact on malaria transmission was observed. The findings suggest that two rounds of MDA in a single year may not be sufficient for a sustained impact on transmission in a pre-elimination setting, especially when the impact of MDA is restricted by imported malaria. Importantly, this study adds to the limited evidence for the use of MDA in low transmission settings in sub-Saharan Africa.

**Additional files**

- **Additional file 1**: Supplementary methods. Treatment guidelines, demographic data collection, and laboratory protocols. (DOCX 766 kb)
- **Additional file 2**: Figure S1. Capillary whole blood piperaquine concentrations at day 7 post-dose, stratified by self-reported adherence status. Figure S2. Number of clinical malaria cases as reported through the malaria case notification system from January 2015 to Sept 2017 in Unguja. Figure S3. Weekly number of clinical malaria cases as reported in the Malaria Early Epidemic Detections System in Unguja 2016. (PDF 414 kb)
- **Additional file 3**: Table S1. Adverse events reported during post-MDA surveys (active detection) and at health facilities (passive detection) after mass treatment with DP and SLD primaquine. Table S2a. Risk factors associated with asymptomatic malaria infection at the baseline of the study. Table S2b. Risk factors associated with asymptomatic malaria infection during the follow-up survey three months after completed MDA. (XLSX 30 kb)

**Abbreviations**

- <LLOQ: Below lower limit of quantification; aOR: Adjusted odds ratios; API: Annual parasite index; CI95%: 95% confidence intervals; CRCTs: Cluster randomised controlled trials; Cytb: Cytochrome b; DOT: Directly observed treatment; DP: Dihydroartemisinin-piperaquine; GEE: Generalised estimating equations; HH: Household; IQR: Interquartile range; IRS: Indoor residual spraying; LLINs: Long-lasting insecticide-treated nets; LLOQ: Lower limit of quantification; MCH: Malaria case notification system; MDA: Mass drug administration; MTAT: Mass testing and treatment; OR: Odds ratio; P. falciparum: Plasmodium falciparum; PCR: Polymerase chain reaction; PQ: Primaquine; qPCR: Quantitative PCR; RDTs: Rapid diagnostic tests; SLD: Single low dose; WHO: World Health Organization

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Funding**

This study was supported by the Erling-Persson Family Foundation. JT is funded by the Wellcome Trust of Great Britain and the Bill and Melinda Gates Foundation. The funders had no role in the study design, data collection, data analyses, data interpretation, or writing of the report.

**Acknowledgements**

We would like to thank all study participants, village leaders, health care workers, and ZAMEP employees for their dedicated participation in the study. We would also like to acknowledge Roly Gosling for the valuable input on study design and Pedro Sanches for the technical support in the field.
Authors’ contributions
UM, MIM, EM, EP, AM, ASA, and ABj participated in the study design. UM, HM, SJS, MK, SMA, and LH supervised the field implementation and data/sample collection. AI, BAS, and UJ conducted the molecular analyses; JT conducted the piperazine concentration analysis. UM analysed the data; ABe and MS assisted in the statistical analyses. UM wrote the manuscript assisted by ABj. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Ethical approval was obtained from the Zanzibar Medical Research and Ethics Committee [ZAMREC/0001/January/2016] and the Zanzibar Food and Drugs Board [No.ZFDB/MMB/LZ/16]. Verbal consent to conduct the study was sought from district authorities and from village leaders prior to the study onset. Written informed consent to participate in the study was sought from the head of household and household members over the age of 16 on the day of the first survey; it was made clear that individual participation in the study was voluntary. Ethical approval for molecular work at Karolinska Institutet was granted by the Regional Ethics Committee in Stockholm, Sweden [2013/636-32].

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, Stockholm, Sweden. 2 Zanzibar Malaria Elimination Programme, Ministry of Health, Zanzibar, Tanzania. 3 Malaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, USA. 4 Biostatistics Unit, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 5 Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Bangkok, Thailand. 6 Nuffield Department of Clinical Medicine, Centre for Tropical Medicine, University of Oxford, Oxford, UK. 7 Department of Women’s and Children’s Health, International Maternal and Child Health, Uppsala University, Uppsala, Sweden.

Received: 9 July 2018 Accepted: 29 October 2018
Published online: 10 December 2018

References
1. WHO: World malaria report. 2016.
2. Okell LC, Bousema T, Griffin JT, Ouedraogo AL, Ghani AC, Drakeley CJ. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun. 2012;3:1237.
3. Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability, transmissibility and public health relevance. Nat Rev Microbiol. 2014;12(12):833–40. https://doi.org/10.1038/nrmicro3364.
4. WHO: Mass drug administration, mass screening and treatment and focal screening and treatment for malaria: WHO Evidence Review Group meeting report. 2015.
5. Cook J, Xu W, Msellem M, Vonk M, Bergstrom B, Gosling R, Al-Mafazy AW, McEloy P, Molteni F, Abbas AK, et al. Mass screening and treatment using a falciparum-specific rapid diagnostic test did not reduce malaria incidence in Zanzibar. J Infect Dis. 2014;211(9):1476–83. https://doi.org/10.1093/infdis/jiu565.
6. Mosha JF, Sturrock HJ, Greenhouse B, Greenwood B, Sutherland CJ, Gadalla N, Atwal S, Drakeley C, Kibidi G, Bousema T, et al. Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics. Malar J. 2013;12:2221.
7. Poirat E, Skarbinski J, Sinclair D, Kachur SP, Lwin KM, Delmas G, Nosten FH, Malaria Elimination Task Force G. Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Cambodian villages. Clin Infect Dis. 2015;60(12):1831–9.
8. Brady OJ, Slater HC, Pemberton-Ross P, Wenger E, Maude RJ, Ghani AC, Penny MA, Gerardin J, White LJ, Chitnis N, et al. The potential contribution of mass drug administration in dihydroartemisinin plus piperquine on malaria in Southern Province Zambia: a cluster-randomized controlled trial. J Infect Dis. 2016;214(12):1831–9.
9. Gosling RD, Okell L, Mosha J, Chandramohan D. The role of antimalarial treatment in the elimination of malaria. Clin Microbiol Infect. 2011;17(11):1617–23.
10. WHO: Mass drug administration for falciparum malaria: a practical field manual. 2017.
11. Shekalaghe SA, Drakeley C, van den Bosch S, ter Braak R, van den Bijaard W, Mwanza C, Semwasa S, Masokoto A, Mosha F, Tekken K, et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malar J. 2011;10:247.
12. von Seidlein L, Walraven G, Milligan PJ, Alexander N, Manneh F, Deen JL, Coleman R, Jawara M, Lindsay SW, Drakeley C, et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Trans R Soc Trop Med Hyg. 2009;103(7):217–25.
13. Landier J, Kajeechiwa L, Thwin MM, Parker DM, Chaumeau V, Wiladphaingern J, Imwong M, Miotto O, Patumrat K, Duanggupama J, et al. Safety and effectiveness of mass drug administration to accelerate elimination of artesinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Welcome Open Res. 2017;2:81.
14. Song J, Socheat D, Tan B, Dana P, Deng C, Sokunthea S, Seila S, Ou F, Jain H, Li G. Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar J. 2010;9:57.
15. Tripura R, Peto T, Nguon C, Davoeung C, Mukala M, Sinthirantomp P, Dhordha M, Promnarate C, Imwong M, von Seidlein L, et al. A controlled trial of mass drug administration to interrupt transmission of multi drug resistant falciparum malaria in Cambodian villages. Clin Infect Dis. 2018;67(6):801–7. https://doi.org/10.1093/cid/ciy196.
16. Landier J, Parker DM, Thu AM, Lvin KM, Delmas G, Nosten FH, Malaria Elimination Task Force G. Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. Lancet. 2018;391(10133):P1916–926.
17. Eisele TP, Bennett A, Silumbke K, Finn TP, Chalwe V, Kamwala M, Hamainza B, Moonga H, Kocema E, Chizema Kawesa E, et al. Short-term impact of mass drug administration and dihydroartemisinin plus piperquine on malaria in Southern Province Zambia: a cluster-randomized controlled trial. J Infect Dis. 2016;214(12):1831–9.
18. Ali AS, Thawer NG, Khatib B, Amier HH, Shija J, Msellem M, Al-Mafazy AW, Baron JC, Haldar S, Biston I, et al. Performance of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. Lancet Glob Health. 2017;5(7):e680–7.
19. Okell LC, Griffin JT, Kleinichmidt I, Hollingsworth TD, Churcher TS, White MJ, Bousema T, Drakeley CJ, Ghani AC. The potential contribution of mass drug administration to control of Plasmodium falciparum malaria. PLoS One. 2011;6(8):e2079.
20. Maude RJ, Socheat D, Nguon C, Saroth P, Dana P, Li G, Song J, Yeung S, Dondorp AM, Day NP, et al. Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and arteisinamin resistance. PLoS One. 2012;7(5):e37166.
21. Bjorkman A, et al., From high to low malaria transmission in Zanzibar - challenges and opportunities to achieve elimination, BMC Medicine, 2018, in press.
22. Morris L, Xu W, Msellem MI, Schwartz A, Abass A, Shakey D, Cook J, Bhattarai A, Petzold M, Greenhouse B, et al. Characterising temporal trends in asymptomatic Plasmodium infections and transporter polymorphisms during transition from high to low transmission in Zanzibar, 2005-2013. Infect Genet Evol. 2015;33:110–7.
23. Ali AS, Thiaw NG, Khatib B, Arner HH, Shija J, Msellem M, Al-Mafazy AW, Garimo IA, Mkuli H, Ramsan MM, et al. Artemisinin combination therapy mass drug administration in a setting of low malaria endemicity: programmatic coverage and adherence during an observational study in Zanzibar. Malar J. 2017;16(1):332.
24. Poirat E, Sohele A, Ntshalintshali N, Mwanendele A, Mikhonta N, Malambe C, Vilakati S, Pan S, Darteh S, Maphalala G, et al. Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study. Malar J. 2016;15(1):384.
25. Xu W, Morris U, Aydin-Schmidt B, Msellem MI, Shakedy D, Petzold M, Bjorkman A, Martensson A, SYBR Green real-time PCR-RFLP assay targeting the plasmodium cytochrome B gene--a highly sensitive molecular tool for...
malaria parasite detection and species determination. PLoS One. 2015;10(3):e0120210.
26. Kamau E, Tolbert LS, Kotaepere L, Pratt M, Nyakoe N, Murray L, Ogutu B, Wailumbi JN, Ockenhouse CF. Development of a highly sensitive genus-specific quantitative reverse transcriptase real-time PCR assay for detection and quantitation of plasmodium by amplifying RNA and DNA of the 18S rRNA genes. J Clin Microbiol. 2011;49(8):2946–53.
27. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. www.OpenEpi.com, updated 2013/04/06, accessed 07 Sept 2018.
28. Mohammed KA, Haji HJ, Gabrielli AF, Mubila L, Bowers G, Chitsulo L, Bradley MH, Engels D, Savioi L, Molyneux DH. Triple co-administration of ivermectin, albendazole and praziquantel in zanzibar: a safety study. PLoS Negl Trop Dis. 2008;2(1):e171.
29. Stothard JR, French MD, Khamis IS, Basanez MG, Rollinson D. The epidemiology and control of urinary schistosomiasis and soil-transmitted helminthiasis in schoolchildren on Unguja Island, Zanzibar. Trans R Soc Trop Med Hyg. 2009;103(10):1031–44.
30. von Seidefin L, Greenwood BM. Mass administrations of antimalarial drugs. Trends Parasitol. 2003;19(10):452–60.
31. Adhikari B, Phrommane K, Kommaray S, Soundala X, Souvanthong P, Pongvongs T, Henriques G, Newton PN, White NJ, Day NPJ, et al. Why do people participate in mass anti-malarial administration? Findings from a qualitative study in Nong District, Savannakhet Province, Lao PDR (Laos). Malar J. 2018;17(1):15.
32. Pell C, Tripura R, Nguon C, Heng C, Daveoung C, Rekol H, von Seidefin L, et al. Community participation during two mass anti-malarial administrations in Cambodia: lessons from a joint workshop. Malar J. 2018;17(1):53.
33. Pell C, Tripura R, Nguon C, Cheah P, Daveoung C, Heng C, Dara L, Sareth M, Dondorp A, von Seidefin L, et al. Mass anti-malarial administration in western Cambodia: a qualitative study of factors affecting coverage. Malar J. 2017;16(1):206.
34. Dial NJ, Ceesa J, Gosling RD, D’Alessandro U, Baltzell KA. A qualitative study to assess community barriers to malaria mass drug administration trials in The Gambia. Malar J. 2014;13:47.
35. Gutman J, Kovacs S, Dorey G, Stergachis A, Ter Kuile FO. Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(2):184–93.
36. Bancone G, Chauwiwat N, Somsakchaicharoen R, Poondpanya L, Moo PK, Gomsavun G, Kaechecha L, Thwin MM, Rakthinthong S, Nosten S, et al. Single low dose primaquine (0.25mg/kg) does not cause clinically significant haemolysis in G6PD deficient subjects. PLoS One. 2016;11(3):e0151886.
37. Bastiaens GJH, Tiono AB, Okebe J, Pett HE, Coulibaly SA, Goncalves BP, Affara M, Ouedraogo A, Bougouma EC, Sanou GS, et al. Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: two open-label, randomized, safety trials. PLoS One. 2018;13(1):e0190272.
38. Kaneko A, Takao G, Kalkoa M, Yaman S, Kobayakawa T, Bjorkman A. Malaria eradication on islands. Lancet. 2000;356(9241):1560–4.
39. Chen I, Gosling R, Drakeley C, Bousema T. Mass drug administration for malaria: a means to what end? J Infect Dis. 2016;214(12):1790–2.
40. UCSF Global Health Group: Review of mass drug administration and primaquine use. 2014.
41. Thomson MC, Ukwuoba I, Hershley CL, Bennett A, Ceccato P, Lyon B, Dinku T. Using rainfall and temperature data in the evaluation of National Malaria Control Programs in Africa. Am J Trop Med Hyg. 2017;97(3_Suppl):32–45.